Elanco Animal Health Incorporated $ELAN Stock Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 21.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 257,573 shares of the company’s stock after buying an additional 45,700 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Elanco Animal Health were worth $5,767,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Anchor Investment Management LLC purchased a new position in Elanco Animal Health in the second quarter worth $29,000. Integrated Wealth Concepts LLC acquired a new position in shares of Elanco Animal Health during the second quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Elanco Animal Health during the 2nd quarter valued at $38,000. Root Financial Partners LLC purchased a new stake in shares of Elanco Animal Health during the 3rd quarter valued at $41,000. Finally, Bessemer Group Inc. boosted its position in shares of Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Kurzius purchased 40,000 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the purchase, the director owned 188,647 shares in the company, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shiv O’Neill acquired 3,998 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was purchased at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by corporate insiders.

Elanco Animal Health Trading Down 0.1%

NYSE ELAN opened at $23.04 on Monday. Elanco Animal Health Incorporated has a 12-month low of $19.40 and a 12-month high of $27.98. The company has a fifty day simple moving average of $23.13 and a two-hundred day simple moving average of $23.82. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The stock has a market cap of $11.51 billion, a P/E ratio of -56.20, a P/E/G ratio of 2.05 and a beta of 1.73.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the company earned $0.26 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts forecast that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Morgan Stanley dropped their target price on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. UBS Group increased their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. The Goldman Sachs Group initiated coverage on Elanco Animal Health in a research note on Friday, October 16th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Jefferies Financial Group downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating and cut their price objective for the company from $31.00 to $24.00 in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus target price of $29.33.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.